DIZAC (diazepam) by Pfizer is mechanism of action although the precise mechanism by which diazepam exerts its antiseizure effects is unknown, animal and in vitro studies suggest that diazepam acts to suppress seizures through an interaction with γ-aminobutyric acid (gaba) receptors of the a-type (gaba a ).
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
DIZAC (diazepam) is an injectable benzodiazepine that acts as a GABA-A receptor agonist to suppress seizure activity and neuronal hyperexcitability. It enhances the binding of GABA, the major inhibitory neurotransmitter in the CNS, allowing chloride influx that reduces neuronal depolarization. DIZAC is indicated for acute seizure management and anxiety disorders requiring rapid onset parenteral therapy.
As a pre-launch product, DIZAC teams are focused on buildout, regulatory finalization, and pre-commercial preparation with modest current headcount.
Mechanism of Action Although the precise mechanism by which diazepam exerts its antiseizure effects is unknown, animal and in vitro studies suggest that diazepam acts to suppress seizures through an interaction with γ-aminobutyric acid (GABA) receptors of the A-type (GABA A ). GABA, the major…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants
Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy
Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán
Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy
A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers
Worked on DIZAC at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on DIZAC offers pre-launch career exposure in a mature asset class with limited upside; roles focus on regulatory execution, market access, and competitive positioning against established generics. Career growth depends heavily on whether DIZAC achieves meaningful differentiation or becomes a commodity entry.